R esearchers at the Cleveland Clinic
have identified what appears to be a powerful gene predictor for cancer among some patients with Cowden syndrome (CS) or Cowden-like syndrome (CLS) -rare, inherited conditions characterized in part by the presence of benign neoplasms throughout the body. Published in the Journal of the American Medical Association in December, the findings show that up to 85% of CS/CLS patients who have breast cancer also have a compromised gene called KILLIN. Moreover, CS/ CLS patients with compromised KILLIN also have much higher risks for kidney cancer than those CS/CLS patients without it.
The study's authors emphasize that other studies must still replicate these fi ndings. But if the results hold up, KILLIN could be one of the strongest genetic cancer risk factors discoveredon par with BRCA1 and BRCA2, albeit for this more limited CS/CLS population, according to the study's corresponding author, Charis Eng, M.D., Ph.D .
"The fi nding has important implications for testing -meaning improved molecular diagnosis of cancer among people with CS/CLS -and also for screening of cancer risk among CS/CLS patients and their relatives," said Eng, who chairs the Cleveland Clinic's genomic medicine institute. "If a CS/CLS patient tests positive in a KILLIN assay, we might lower the threshold for prophylactic mastectomy because it can be hard to distinguish breast cancer from the many benign nodules that characterize these conditions."
Rare Problem
CS affl icts an estimated 1 in 200,000 people worldwide. The true prevalence might be greater because many of its featuresincluding an enlarged head; benign neoplasms on the face, hands, and feet; autism; and breast, kidney, and thyroid cancersalso occur in the general population, and not all such people are investigated for CS. Detecting the disease isn't easy. Patients are diagnosed according to their ranking on a scoring system that lists more than a dozen criteria. CLS patients have some, but not all, of the defi ning CS features. Roughly 80% of CS cases (but only 5% -10% of CLS cases) are caused by inherited germline mutations in the phosphatase and tensin (PTEN) homolog gene. PTEN mutations are inherited in an autosomal-dominant manner, meaning that the allele passed down by one parent is affected, whereas the allele passed down by the other parent is normal. Like KILLIN, PTEN is a tumor suppressor gene, coding for a protein that ordinarily helps to regulate and promote programmed cell death, or apoptosis. Although the precise mechanisms remain poorly understood, researchers think that inherited PTEN mutations produce CS's characteristic lesions, known as hamartomas, whereas later damage to the otherwise healthy second allele, and perhaps to other genes, leads to full-blown cancer in CS/CLS patients. "But why in a tissue-specifi c manner? We don't know," Eng said.
Eng came across KILLIN while looking for the genetic cause of CS among patients who don't have germline PTEN mutations. She and her team started with 2,000 CS/CLS patients in the United States. From that group, they selected 123 individuals with pristine PTEN and an absence of nearby germline anomalies. Eng's initial hypothesis was that although these patients don't have mutated PTEN, perhaps epigenetic mutations -methyl groups sticking to the sequence that interfere with the gene's ability to make protein -could compromise the gene.
The team did fi nd that PTEN is often hypermethylated, meaning that the methyl groups stick to its promoter, the "on switch" for protein transcription. Unexpectedly, though, PTEN could still function normally despite these methyl groups. But when Eng looked more closely at the surrounding sequences, she found that hypermethylation had compromised PTEN's next-door neighbor: KILLIN. From that fi nding, she 
New Epimutation
More intriguing than the screening implications of Eng's fi ndings, in Offi t's view, are their implications for research into familial cancer syndromes. The fi ndings appear to show that PTEN/KILLIN hypermethylation can be inherited -making it one of the few examples of a gene risk factor passing through generations with no change to DNA. This example is now the third of an inherited epigenetic mutation involved in the mechanism for cancer susceptibility, Offi t said. The other two target the MSH2 and MHL1 genes, both implicated in familial colon cancer.
Such epimutations pose vexing challenges for genetic counseling. For instance, whereas inheritance of MSH2 epimutations follows a straightforward, autosomaldominant (i.e., Mendelian) pattern, non-Mendelian inheritance has been observed for MSH1, possibly because methylation is reversible. "So, when we fi nd epimutations in MSH1, we advise testing of as many family members as possible and intensifi ed colon cancer screening for those found to carry the mutation," he said.
Eng's results, Offi t added, suggest a possible Mendelian inheritance pattern for KILLIN, but the data are so far too limited to state this conclusively. Therefore, the possibility of more complex transmission patterns remains. "It seems prudent to follow the MSH1 model and test as many PTEN wild-type CS family members for KILLIN as possible, until the mode of transmission can be worked out," he said.
Eng said she plans to continue testing CS family members for KILLIN hypermethylation and that she has assembled a new cohort to test the validity of her fi ndings.
